A melanocytic diagnostic cocktail that contains antibodies against Melan-A, PNL-2, TRP-1, and TRP-2 has been shown to improve the overall sensitivity to 93.9% when differentiating from soft tissue sarcomas, while maintaining 100% specificity, and represents the current gold standard for diagnosing amelanotic melanocytic neoplasms in dogs [3,18]. This evidence concerns the gene MLANA and soft tissue sarcoma.